OTIS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Otis Worldwide Corp is not a strong buy at the moment for a beginner investor with a long-term horizon and $50,000-$100,000 to invest. While the company has shown positive financial performance and offers dividends, the technical indicators are bearish, options sentiment is negative, and recent analyst ratings and price target revisions suggest caution. The stock is better suited for monitoring rather than immediate investment.
The technical indicators for OTIS are bearish. The MACD histogram is negative and contracting, RSI is neutral at 24.131, and moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 77.921) with a pre-market price of 78.25, suggesting limited upside potential in the short term.
Hedge funds are significantly increasing their positions, with a 676.26% increase in buying over the last quarter.
The company has demonstrated strong financial performance in Q4 2025, with revenue up 3.29% YoY, net income up 10.98% YoY, and EPS up 13.10% YoY.
Otis has increased its quarterly dividends by 8% YoY, providing a 2.1% dividend yield and a total shareholder yield of 4.7% through buybacks.
Insiders are selling heavily, with a 4363.40% increase in selling activity over the last month.
Analyst sentiment is mixed to negative, with recent downgrades and price target reductions citing weaker-than-expected guidance and sub-par organic profit growth.
The bearish technical indicators and negative options sentiment further weigh against the stock.
In Q4 2025, Otis Worldwide reported revenue of $3.796 billion (up 3.29% YoY), net income of $374 million (up 10.98% YoY), EPS of $0.95 (up 13.10% YoY), and a gross margin of 30.22% (up 3.60% YoY). These figures indicate solid financial growth and operational efficiency.
Analyst sentiment is mixed. BNP Paribas initiated coverage with an Outperform rating and a $109 price target, citing Otis as a preferred play in the elevator sector. However, JPMorgan downgraded the stock to Neutral with a reduced price target of $98, citing weaker guidance and missed sales in Q4. Barclays also lowered its price target to $90, maintaining an Underweight rating due to sub-par organic profit growth.
